title: [Risk factors and prevention of retinopathy of prematurity].
abstract: The history of retinopathy of prematurity (ROP) gives a prime example of how dangerous the uncontrolled introduction of a new medical treatment--particularly in the field of neonatology--may be. The most important risk factors for the development of ROP are the immaturity of premature infants as well as uncontrolled and/or inadequate treatment with oxygen. In comparison to the fetus, the premature infant is exposed to a nonphysiologically high oxygen concentration. This hyperoxia leads to formation of aggressive oxygen radicals on the one hand and, on the other hand, to temporarily reduced production of growth factors such as vascular endothelial growth factor and erythropoietin, which both play an important role in the pathogenesis of ROP. The most important measure to prevent ROP is restrictive and carefully monitored oxygen treatment. Medical treatment to prevent ROP includes injection of D-penicillamine and retinol, but the available data are still limited, particularly with regard to the long-term effects of this treatment. A higher oxygenation in prethreshold ROP does not lead to recovery of ocular findings, but it increases the incidence of pulmonary complications. A reduction of light intensity in neonatal intensive care units proved not to be efficient for preventing ROP. To avoid blindness, standardized screening of the risk group is needed.
authors.affiliation: Zentrum für Kinder- und Jugendmedizin, Philipps-Universität Marburg, Baldingerstrasse, 35033 Marburg.
authors.forename: L
authors.initials: L
authors.lastname: Pelken
authors.forename: R F
authors.initials: RF
authors.lastname: Maier
mesh_terms: D017707:Erythrocyte Transfusion / Q000009:adverse effects; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D005865:Gestational Age; D006801:Humans; D018496:Hyperoxia / Q000150:complications; D007231:Infant, Newborn; D019190:Iron Overload / Q000150:complications; D008403:Mass Screening; D010102:Oxygen Inhalation Therapy / Q000009:adverse effects / Q000379:methods; D011994:Recombinant Proteins; D012017:Referral and Consultation; D012178:Retinopathy of Prematurity / Q000209:etiology* / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin